2025 Transatlantic Exchange by Dana-Farber and Gustave Roussy to Focus on Radioligand Therapy
Dana-Farber Cancer Institute and Gustave Roussy (Villejuif, France) have announced the 2025 Transatlantic Exchange scientific program, with a focus on Radioligand Therapy.
The Fourth Transatlantic Exchange in Oncology Conference, titled “Radiopharmaceutical Therapy Meets Oncology,” will take place on March 19, 2025, at the Hyatt Regency Etoile Hotel in Paris, France, and will be livestreamed globally.
The conference, supported by L’Institut Servier, will feature leading experts from both institutions, renowned worldwide for their contributions to oncology.
Key topics include Precision Oncology and molecular imaging for early detection, the development of Radio-labeled active products, the latest clinical applications, and perspectives from academia and industry on Radioligand Therapies.
The keynote speaker will be Michael Morris, Prostate Cancer Section Head at Memorial Sloan Kettering Cancer Center (NYC, USA), who will discuss “Seeing Beyond VISION: Designing Radioligand Therapy Trials that Yield a Survival Benefit.”
This conference is part of a collaboration between Dana-Farber and Gustave Roussy, with the support of L’Institut Servier, a non-profit organization dedicated to advancing healthcare through academic research and scientific exchange.
The partnership includes annual conferences alternating between Boston, MA, USA, and Paris, France, as well as a biennial fellowship program for young researchers and post-doctoral students from Gustave Roussy, who are hosted in Dana-Farber’s research laboratories.
Previous conferences have focused on Immuno-Oncology, AI/Data Science in Oncology, and Liquid Biopsy, with the inaugural meeting held in Boston in May 2022.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023